31 results about "Bone marrow source" patented technology

Disclosed are methods of treating traumatic brain injury in a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

Disclosed are methods of treating infertility or increasing fertility of a female subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

Disclosed are methods of treating perianal fistula a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

Disclosed are methods of improving perioral and face fat graft retention in a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

The invention provides application of apoptotic cell pretreated macrophages in preparation of an osteoarthritis treatment preparation, a cell preparation and a preparation method, and relates to the technical field of biomedicine.In the embodiment of the invention, based on a mouse development model and an osteoarthritis (OA) model, it is found that in the area away from the cartilage surface, the apoptotic cell pretreated macrophages are subjected to apoptotic cell pretreatment, and the apoptotic cell pretreated macrophages are subjected to apoptotic cell pretreatment in the area away from the cartilage surface; in the macrophages, the content of the interment-related LAMP1 protein is obviously higher than that of the macrophages close to the cartilage surface area, and the expression results of TGF-beta 1 and LRG1 are respectively opposite and consistent with those of the LAMP1. The invention also finds that after the chemotactic effect of apoptotic cells on macrophages is weakened, the cellular burial effect is limited, and the cartilage matrix development disorder is caused. Based on development process inspiration, the invention provides a treatment strategy: bone marrow-derived macrophages pretreated by apoptotic cells are injected into articular cavities, and a good cartilage regeneration treatment effect can be achieved in a mouse arthritis model. In addition, the bone marrow-derived macrophages pretreated by apoptotic cells can still express TGF-beta1 after being injected into the body for 3 days, so that the effect of continuously promoting cartilage regeneration is achieved.

A polyclonal antibody composition specifically binds the pTonB epitope (SEQ ID NO: 11) from Acinetobacter baumannii and is elicited by immunization with a multi-epitope antigen comprising thioredoxin leader, rigid linker, and kernels including SEQ ID NOs: 6, 7, 11, 12, and 8. These antibodies enhance opsonophagocytic killing of A. baumannii Ci79 via classical complement activation and Fey receptor-mediated phagocytosis by bone marrow-derived macrophages. Absorption of pTonB-specific antibodies reduces killing by >70%, confirming epitope dominance. Passive transfer of the composition protects >60% of mice in a lethal intranasal challenge model. Pharmaceutical compositions, treatment methods (alone or with antibiotics like colistin), prophylactic uses, diagnostic kits, and polyclonal compositions are disclosed for combating multidrug-resistant A. baumannii infections.

The invention belongs to the technical field of medical materials and tissue regeneration engineering, and provides a composite hydrogel prepolymerization solution and application thereof, and composite hydrogel and application thereof. The composite hydrogel pre-polymerization liquid provided by the invention is prepared from the following components in concentration: 5 to 10 w / v percent of methacrylic anhydride gelatin, 1 to 4 w / v percent of methacrylated hyaluronic acid, 0.5 to 1.5 w / v percent of hectorite, 0.5 to 1.5 w / v percent of a photoinitiator and 20 to 100 nmol / L of sphingosine-1-phosphoric acid loaded nano vesicles based on sphingosine-1-phosphoric acid, the nano vesicles are formed by bone marrow-derived macrophages. The composite hydrogel formed by the composite hydrogel pre-polymerization liquid has good biocompatibility and controllable release performance, can form a stable barrier environment on a wound surface, and significantly accelerates the wound surface healing process through the dual effects of immune regulation and revascularization.

The invention belongs to the technical field of biological medicines, and particularly relates to application of emipril in preparation of a medicine for improving choroidal neovascularization related diseases. The invention aims to solve the problems of strong invasiveness and limited curative effect of the existing therapy. It is found that emipril can achieve differential regulation and control on a CD26 system in vivo, that is, the enzyme activity of CD26 in bone marrow is improved, the enzyme activity of CD26 in peripheral blood is reduced, the concentration gradient of stromal cell-derived factor-1 can be established between the bone marrow and the peripheral blood through differential regulation and control, and the concentration gradient of the stromal cell-derived factor-1 can be further improved. The bone marrow-derived cells are driven to homing to eye lesions and differentiate into repair cells, so that eye diseases are repaired or improved, meanwhile, the collection and migration of bone marrow-derived macrophages to CNV regions can be increased, and the anti-inflammatory effect is achieved. According to the application, an endogenous repair mechanism is activated through non-invasive administration, and a safer and more effective treatment method is provided for related eye diseases.

Disclosed are methods of treating perianal fistula a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an antiviral drug acyclovir in preparation of a tumor immunotherapy drug. According to the invention, acyclovir is utilized to induce macrophages to become an M1 phenotype, the phagocytic function and the antigen presentation capability of the macrophages are enhanced, and the maturation of dendritic cells is promoted, so that the anti-tumor effect is realized. In an effective concentration which is non-toxic to a macrophage line RAW264.7, acyclovir significantly promotes phenotype transformation of macrophages to M1, and significantly enhances the cell phagocytic ability and antigen presentation ability of the macrophages. Meanwhile, the acyclovir in an effective concentration can also remarkably promote maturation of bone marrow-derived dendritic cells, so that new application of the acyclovir in the field of tumor immunotherapy is found. According to the method, the application range of acyclovir and immune cell immunotherapy is expanded, and a new feasible clinical treatment scheme is provided for anti-tumor immunotherapy.

The invention discloses application of curcumenone in preparation of a medicine for preventing and treating ischemia-reperfusion injury. The invention proposes and verifies that the caramel curcumenone can be used for preventing and treating the hepatic ischemia reperfusion injury for the first time, and the compound can effectively protect hepatic tissues and avoid liver function damage by inhibiting the oxidative stress level of the hepatic tissues after ischemia reperfusion, avoiding cell ferroptosis and improving bone marrow-derived macrophages, so that the caramel curcumenone can be used for preventing and treating the hepatic ischemia reperfusion injury. The invention provides a novel medicine with great application potential for preventing and treating ischemia reperfusion injury.

Disclosed are methods of treating infertility or increasing fertility of a female subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

The present disclosure relates to a composition for three-dimensional cell and / or organoid culture, comprising a phase-changing matrix comprising a partially ordered polypeptide, and a plurality of cells encapsulated in the matrix. In embodiments, the plurality of cells comprises one or more cell types, including at least one cell type selected from the group consisting of: bone-marrow derived mesenchymal stem cells and adipose-derived mesenchymal stem cells. In embodiments, the one or more cell types comprises mesenchymal stem cells, the partially ordered polypeptide comprises at least one chemically-interactive sequence such as arginylglycylaspartic acid (RGD) sequence, the matrix forms a porous network when heated above a transition temperature, and the partially-ordered polypeptide comprises a plurality of structured domains, and a plurality of disordered domains.

The present invention addresses the problem of providing a novel therapeutic agent that is effective against diseases involving stratified squamous epithelial cells such as dry eye syndrome. The present invention is an agent for promoting normal differentiation / maturation of stratified squamous epithelial cells, which comprises a secretion of mesenchymal stem cells. It is preferable that the secretions not include animal serum, that the mesenchymal stem cells be adipose-derived mesenchymal stem cells, umbilical cord-derived mesenchymal stem cells, or bone marrow-derived mesenchymal stem cells, and that the stratified squamous epithelial cells be at least one selected from the group consisting of corneal epithelial cells, conjunctival epithelial cells, epidermal keratinocytes, oral epithelial cells, epiglottic epithelial cells, esophageal epithelial cells, vaginal epithelial cells, vocal fold epithelial cells, nasal epithelial cells, and nasal vestibular epithelial cells.

The invention discloses a preparation method and application of a novel macrophage for treating myocardial infarction, and belongs to the fields of cell engineering, nanotechnology, material science, immunology and the like. According to the invention, bone marrow-derived macrophages are induced to be polarized to M2 type and are subjected to magnetic modification, so that the macrophages are endowed with the capability of efficiently expressing vascular endothelial growth factors, Mag M2-M-VEGF cells are obtained, and proliferation of endothelial cells and formation of collateral vessels are promoted through local high expression of VEGF at a myocardial infarction part, so that local ischemia injury is relieved. According to the invention, precise targeted delivery of cells is realized, local inflammatory response is inhibited, and blood perfusion in an infarction area is improved. The medicine is endowed with magnetic targeting capacity by internalizing Fe3O4 NPs and is accurately enriched in myocardial infarction tissue under the guidance of a magnetic field, M2 type polarization inhibits pro-inflammatory reaction by reducing pro-inflammatory factor release and releasing a large amount of anti-inflammatory factors, and meanwhile, VEGF is specifically secreted, angiogenesis of an infarction part is promoted, and the capillary density of an infarction region is effectively increased.

Disclosed are methods of treating perianal fistula a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

The invention discloses an immortalized goat bone marrow-derived macrophage for expressing an SV40LT gene and application of the immortalized goat bone marrow-derived macrophage, and belongs to the technical field of bioengineering. The immortalized goat bone marrow-derived macrophage provided by the invention is obtained by knocking an immortalized gene SV40LT into a primary goat bone marrow-derived macrophage ROSA26 site through a CRISPR-Cas 9 system, and the immortalized goat macrophage provided by the invention is an immortalized goat macrophage cell strain which is suitable for being infected with salmonella and brucella and can be continuously and stably passaged; the method can be effectively applied to immunological research on goat brucella infection resistance and production of brucella vaccines.

Disclosed are methods of treating perianal fistula a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

The present invention relates to a composition comprising C-C motif chemokine ligand 5 (CCL5) for promoting the activation of bone marrow-derived stem cells. It is identified that, when CCL5, which is a niche-enhancing factor, is injected together with growth related oncogene beta (GROβ), which is known to promote the mobilization of hematopoietic stem cells from the bone marrow into peripheral blood, and AMD3100, which is a CXCR4 antagonist, the migration of hematopoietic stem cells from bone marrow to peripheral blood increases, and the engraftment rate also increases when the hematopoietic stem cells are injected into recipients undergoing bone marrow transplantation. Therefore, the CCL5 protein, GROβ, and the CXCR4 antagonist AMD3100 are provided as a composition for promoting the activation of bone marrow-derived stem cells, and thus bone marrow-derived stem cells activated thereby is provided as a novel therapeutic means for bone marrow diseases requiring bone marrow transplantation.

Disclosed herein are methods of treating complex regional pain syndrome in a subject by administering a therapeutic MSC secretory group product prepared by a method comprising culturing a bone marrow-derived MSC under conditions comprising an oxygen tension of less than 5% and a culture medium having a pH of less than 7.

The invention relates to the technical field of natural product extraction, in particular to a torreya grandis crude polysaccharide extraction method and application of the torreya grandis crude polysaccharide in neuronal differentiation.The torreya grandis crude polysaccharide is extracted through an ultrasonic wave-microwave-enzyme method combined auxiliary extraction technology, the polysaccharide content is detected to be 67.92% through a phenol-sulfuric acid method, the relative molecular mass is 3000 kDa, and the content of the polysaccharide in the torreya grandis crude polysaccharide is 87.92%. A novel method is provided for a torreya grandis polysaccharide extraction process; besides, activity research is carried out on the extracted torreya grandis crude polysaccharide, the torreya grandis crude polysaccharide can promote bone marrow-derived mesenchymal stem cells (BMSCs) to differentiate into neuronal cells, mRNA expression of neuron specific markers Netin, MAP2 and VEGF-A in the BMSCs is increased, the protein level of neuronal differentiation related genes beta-tubin III, Thy-1 and Enolase is up-regulated, and the effect of promoting the differentiation of the neuronal cells is achieved. A good nerve repairing effect is embodied, and the material is expected to be applied to clinical treatment of nerve diseases.

Disclosed herein are methods of treating amyotrophic lateral sclerosis in a subject by administering a therapeutic MSC secretory group product prepared by a method comprising culturing a bone marrow-derived MSC under conditions comprising an oxygen tension of less than 5% and a culture medium having a pH of less than 7.

The invention belongs to the technical field of biological detection, and provides a chemokine detection kit and a preparation method and application thereof, and the detection kit comprises a capture antibody, a detection antibody, a mixed protein standard substance, a diluent and a washing buffer solution. The capture system is used for preparing a capture antibody coupled with a fluorescence coding microsphere by coupling a biotinylated antibody with a fluorescence microsphere coated with biotin, and the detection system is used for preparing a fluorescence labeled antibody by coupling derivatized phycoerythrin PE-SMCC with a specific thioether bond of a sulfhydrylated antibody. The mixed protein standard substance adopts a freeze-drying protection system containing BSA, trehalose and the like. The single hole of the kit can synchronously detect various cytokines, the sample dosage is only 25 microliters, the kit is suitable for detecting chemotactic factors in a mouse in-vitro bone marrow-derived macrophage (BMDM) polarization model, compared with a traditional ELISA method, the efficiency is improved by 10 times, the cost is reduced, and the kit has the remarkable advantages of high flux, wide linear range and high stability.

The invention discloses a culture medium for promoting differentiation of mesenchymal stem cells and a culture method, and belongs to the technical field of biology. The culture medium comprises a basic culture medium, beta-nicotinamide mononucleotide (0.3 to 6.0 mM), atractylenolide II (3 to 10 nM), BMP-4 (1 to 5 ng / mL) and glutathione (50 to 100 [mu] g / mL). Osteogenic differentiation related signal pathways are activated through the synergistic effect of multiple factors, and the differentiation efficiency is remarkably improved to 85% or above. Experiments show that the culture medium has a remarkable effect in bone marrow-derived mesenchymal stem cells, the calcification area is increased by 19.9% compared with that of a basic culture medium, the problems of low efficiency and high cost of a single inducible factor in the prior art are solved, and the culture medium is suitable for bone tissue engineering and clinical bone defect repair and has wide clinical application value.

This invention belongs to the field of regenerative medicine technology, specifically relating to bone marrow-derived macrophages expressing CD301b, TIMD4, and LYVE-1, their preparation method, and applications. The steps are as follows: Primary mouse bone marrow mononuclear precursor cells are cultured in expansion medium for 7 days to obtain macrophages, with the medium changed every 2-3 days during this period; on the 7th day, the expansion medium is replaced with a high-efficiency induction medium and cultured for 46-50 hours to obtain bone marrow-derived macrophages expressing CD301b, TIMD4, and LYVE-1. This invention, through a time-series strategy of TGF-β pre-induction combined with IL-4 / IL-5 / IL-13 synergistic induction, can significantly enhance the expression levels of CD301b, TIMD4, and LYVE-1 in BMDM, making their function close to that of natural cardiac resident macrophages, and effectively exerting anti-inflammatory, repair-promoting, and ventricular remodeling-inhibiting effects after AMI.

The application belongs to the technical field of biomedicine, and discloses a construction method of a mouse model simulating senile osteoarthritis and application thereof, wherein mouse bone marrow cells are induced to differentiate into bone marrow-derived macrophages in vitro, the macrophages are treated with an induction medium containing 100nM doxorubicin for 2 days, and then cultured in a conventional medium for 5 days to obtain senescent macrophages with a stable senescence phenotype; 1x10 6 The senescent macrophages are injected into the knee joint cavity of a mouse once a week for a total of 4 times to induce chronic low-grade inflammation and characteristic osteoarthritis lesions in the joint. The model constructed by the application has high pathological simulation degree, good repeatability, and a modeling cycle of only 4 weeks, thereby reducing the interference of acute injury factors, and can be widely applied to the research on pathogenesis of senile osteoarthritis, screening of therapeutic targets, and evaluation of the efficacy of candidate drugs.

The invention discloses an exosome vesicle for enhancing the curative effect of liver cancer immunotherapy as well as a preparation method and application of the exosome vesicle. The invention provides an application of an exosome vesicle containing miR-32-5p in preparation of a medicine for treating liver cancer or enhancing a liver cancer immunotherapy curative effect. A preparation method of the exosome vesicle comprises the following steps: introducing a miR-32-5p simulant into bone marrow-derived macrophage (BMDM) through transfection, and constructing a BMDM cell line of stable overexpression miR-32-5p, culturing, collecting cell culture supernatant, and separating and purifying to obtain the exosome vesicle. In-vivo and in-vitro experiments show that the exosome miR-32-5p has the functions in TME regulation, immune regulation and HCC progress, the exosome miR-32-5p can enhance HCC immunotherapy, a better treatment strategy is provided for clinical treatment of HCC, especially TACE drug-resistant HCC, and the exosome miR-32-5p has a good application prospect.

The invention discloses a preparation method and application of a dendritic cell-derived exosome, and the preparation method comprises the following steps: (1) inducing in vitro differentiation of bone marrow-derived dendritic cells (DCs) to tolerant dendritic cells (tolDCs) through interleukin-10, and ensuring that the tolDCs highly express key antioxidant and anti-inflammatory proteins, namely, heme oxygenase-1 (HO-1); (2) separating and purifying an exosome HO-1 high-tolDex from the cell culture supernatant of the tolDCs (HO-1 high-tolDCs) with high expression of the HO-1 by virtue of methods such as ultracentrifugation and the like; (3) carrying out comprehensive physicochemical property and biological function identification on the prepared HO-1high-tolDex, and (4) verifying that the HO-1high-tolDex can effectively inhibit excessive activation and inflammatory response of target cells through an in-vitro cell experiment and an in-vivo experiment of a systemic lupus erythematosus (SLE) animal model, alleviate immune pathological injury of model animals, inflammation of kidneys and oxidative stress injury, and improve the bioavailability of the model animals. The immune tolerance is induced; the cell-free immunomodulator is a new generation of efficient and safe cell-free immunomodulator.

The invention provides an anti-tumor and bone repair immunoregulation stent as well as a preparation method and application thereof, and belongs to the technical field of tissue engineering implant materials. According to the invention, an HBC network containing MCSF / CSF-1R and CD47 / SIPR alpha pathway blocking drug co-delivery system is assembled on an aldehyde-rich 3D printing calcium phosphate skeleton, and a therapeutic implant capable of activating macrophages swallowing tumor cells in stages and promoting bone regeneration is developed. The implant shows effective combination with the surface of a monocyte / macrophage, meanwhile, M2 polarization of bone marrow-derived monocyte is remarkably inhibited, and the phagocytic ability of the macrophage to tumor cells is enhanced. The two drugs loaded by the co-delivery system can play a synergistic role to efficiently resist tumors; the decomposed delivery carrier can promote bone regeneration. In an in-vivo tumor treatment model, the treatment stent significantly reduces local M2 macrophages and inhibits tumor growth. In an in vivo tissue regeneration model, the treatment scaffold promotes uniform bone growth.

The present invention discloses a tumor recurrence risk stratification kit based on bone marrow spleen neutrophil ARG1 expression, and relates to the technical field of tumor recurrence risk stratification kits, the tumor recurrence risk stratification kit comprises: a flow cytometry detection module containing the following antibodies coupled with a fluorescent dye: an anti-human CD62L antibody for identifying bone marrow-derived neutrophil; the anti-human CD44 antibody is used for recognizing spleen-derived neutrophil; the anti-human ARG1 antibody is used for detecting the ARG1 expression of the neutrophil; the enzyme-linked immunosorbent assay (ELISA) module contains a reagent for quantitatively detecting the concentration of ARG1 protein in a neutrophil culture supernatant. By accurately determining the expression difference of bone marrow and spleen neutrophil ARG1 of a postoperative patient, dual dimensions of a source function are directly associated with a tumor recurrence risk for the first time; the detection sensitivity and the operation convenience are ensured by utilizing a flow type platform and an ELISA (Enzyme-Linked Immuno Sorbent Assay) double platform; and the multi-center consistency and real-time clinical decision support are further ensured by a matched quality control system and a cloud intelligent interpretation platform.